Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
VICL's Cash-to-Debt is ranked higher than
98% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. VICL: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
VICL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.83  Med: 26.86 Max: No Debt
Current: No Debt
Equity-to-Asset 0.86
VICL's Equity-to-Asset is ranked higher than
77% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. VICL: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
VICL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.88 Max: 0.97
Current: 0.86
0.36
0.97
Interest Coverage No Debt
VICL's Interest Coverage is ranked higher than
98% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VICL: No Debt )
Ranked among companies with meaningful Interest Coverage only.
VICL' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -8.35
Beneish M-Score: -1.52
WACC vs ROIC
9.05%
-98.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -63.15
VICL's Operating Margin % is ranked higher than
54% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. VICL: -63.15 )
Ranked among companies with meaningful Operating Margin % only.
VICL' s Operating Margin % Range Over the Past 10 Years
Min: -730.44  Med: -179.55 Max: -26.06
Current: -63.15
-730.44
-26.06
Net Margin % -61.75
VICL's Net Margin % is ranked higher than
54% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. VICL: -61.75 )
Ranked among companies with meaningful Net Margin % only.
VICL' s Net Margin % Range Over the Past 10 Years
Min: -651.2  Med: -177.91 Max: -24.26
Current: -61.75
-651.2
-24.26
ROE % -20.01
VICL's ROE % is ranked higher than
61% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. VICL: -20.01 )
Ranked among companies with meaningful ROE % only.
VICL' s ROE % Range Over the Past 10 Years
Min: -57.41  Med: -33.83 Max: -11.68
Current: -20.01
-57.41
-11.68
ROA % -18.16
VICL's ROA % is ranked higher than
60% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. VICL: -18.16 )
Ranked among companies with meaningful ROA % only.
VICL' s ROA % Range Over the Past 10 Years
Min: -49.31  Med: -30.49 Max: -10.28
Current: -18.16
-49.31
-10.28
ROC (Joel Greenblatt) % -150.61
VICL's ROC (Joel Greenblatt) % is ranked higher than
60% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. VICL: -150.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VICL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -472.35  Med: -298.96 Max: -113.48
Current: -150.61
-472.35
-113.48
3-Year Revenue Growth Rate 17.70
VICL's 3-Year Revenue Growth Rate is ranked higher than
69% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. VICL: 17.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
VICL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -39.7  Med: 2.35 Max: 37.1
Current: 17.7
-39.7
37.1
3-Year EBITDA Growth Rate -37.90
VICL's 3-Year EBITDA Growth Rate is ranked lower than
87% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. VICL: -37.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
VICL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -56  Med: 2.55 Max: 42.6
Current: -37.9
-56
42.6
3-Year EPS without NRI Growth Rate -37.00
VICL's 3-Year EPS without NRI Growth Rate is ranked lower than
83% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. VICL: -37.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
VICL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.4  Med: -1.4 Max: 50.2
Current: -37
-52.4
50.2
GuruFocus has detected 3 Warning Signs with Vical Inc $VICL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VICL's 10-Y Financials

Financials (Next Earnings Date: 2017-06-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

VICL Guru Trades in Q1 2016

Jim Simons 2,073,599 sh (+29.84%)
John Rogers 5,537,755 sh (-20.34%)
» More
Q2 2016

VICL Guru Trades in Q2 2016

Jim Simons 291,909 sh (+40.77%)
John Rogers 528,991 sh (-4.48%)
» More
Q3 2016

VICL Guru Trades in Q3 2016

Jim Simons 357,009 sh (+22.30%)
John Rogers 529,913 sh (+0.17%)
» More
Q4 2016

VICL Guru Trades in Q4 2016

Jim Simons 392,509 sh (+9.94%)
John Rogers 467,544 sh (-11.77%)
» More
» Details

Insider Trades

Latest Guru Trades with VICL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:AVIR, OTCPK:PKTX, OTCPK:WLDFF, NAS:EYEG, OTCPK:BIVI, NAS:CERU, NAS:ONCS, OTCPK:DMCAF, NAS:ICCC, NAS:ABIO, OTCPK:BIOAF, OTCPK:MRNA, OTCPK:BRTX, OTCPK:CVALF, NAS:PRAN, NAS:NEOT, NAS:GALE, NAS:CYAN, AMEX:OGEN, OTCPK:EMIS » details
Traded in other countries:VCC1.Germany,
Headquarter Location:USA
Vical Inc is engaged in research and development of biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Vical researches and develops both preventative and therapeutic vaccine therapies for cancer and infectious diseases. The company is independently developing a vaccine for metastatic melanoma, cytomegalovirus, and pandemic influenza. It has partnered with large pharmaceutical firms and the National Institute of Health to develop vaccines for cancer as well as heart disease, HIV, and the Ebola virus.

Top Ranked Articles about Vical Inc

Vical to Host Virtual Research & Development Day on May 2, 2017
Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial
Vical to Provide Company Update at the 29th Annual ROTH Conference
SAN DIEGO, March 10, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (NASDAQ:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook at 12:30 p.m. PT on Wednesday, March 15, at the 29th Annual ROTH Conference (Newport Beach, California March 12 – 15). A webcast of the company’s presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact:         
Tony Ramos
(858) 646-1127
Website: www.vical.com

Read more...
Vical Reports Fourth Quarter 2016 Financial Results
SAN DIEGO, March 09, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (NASDAQ:VICL) today reported financial results for the three and twelve months ended December 31, 2016. Net loss for the fourth quarter of 2016 was $2.8 million, or $0.25 per share, compared with a net loss of $2.4 million, or $0.26 per share, for the fourth quarter of 2015. Revenues for the fourth quarter of 2016 were $3.2 million, which was primarily comprised of revenues from Astellas Pharma Inc. for services performed under the ASP0113 collaboration agreements, compared with revenues of $6.8 million for the fourth quarter of 2015. Revenue for 2015 included $4.1 million of non-recurring revenue from IPPOX for the manufacture of an HIV vaccine.
Vical had cash and investments of $41.0 million at December 31, 2016. The Company’s net cash use for 2016 was $8.8 million, which was consistent with the Company’s full year cash burn guidance of between $8 million and $11 million. The Company is projecting net cash burn for 2017 between $8 million and $11 million.Operational updates include:CMV Vaccine – ASP0113Recruitment in the multinational Phase 3 registration trial in hematopoietic cell transplant (HCT) recipients met its target enrollment of 500 subjects in September 2016. The primary endpoint of the trial is a composite of overall mortality and CMV end organ disease which will be assessed one year after transplantation. Astellas expects top-line data to be available in the first quarter of 2018. Vical and Astellas continue to make progress towards a potential BLA filing in 2018. As a reminder, ASP0113 is the first CMV vaccine to enter a pivotal Phase 3 trial.HSV-2 Vaccine – VCL-HB01Recruitment in our Phase 2 trial of the VCL-HB01 HSV-2 therapeutic vaccine is proceeding according to plan. VCL-HB01 is a Vaxfectin®-formulated bivalent vaccine encoding full-length HSV-2 antigens gD and UL46. The 2:1 randomized, double-blind, placebo-controlled trial is being conducted at approximately 15 U.S. clinical sites and will evaluate the efficacy and safety of the vaccine in approximately 225 otherwise healthy adults aged 18 to 50 years with symptomatic genital HSV-2 infection. The primary endpoint of the study is annualized lesion recurrence rate which is a clinically meaningful endpoint for both patients and treating physicians as it provides important information on both the number and spacing of recurrences over time in this chronic disease setting. We expect the top-line data to be available in the second quarter of 2018.VL-2397 – Drug for Invasive Fungal Infections Vical has completed its first-in-human Phase 1 trial of its novel antifungal, VL-2397. The randomized, double-blind, placebo-controlled trial was designed to evaluate safety, tolerability and pharmacokinetics of single and multiple ascending doses of intravenous VL-2397 in approximately 90 healthy volunteers. Preliminary results point to a favorable safety and pharmacokinetic profile for VL-2397. We expect to present the full data set at an upcoming scientific conference in 2017. In preclinical studies, VL-2397 has demonstrated rapid and potent antifungal activity against a range of invasive fungal pathogens, including frequently-occurring Aspergillus species, azole-resistant Aspergillus fumigatus, Candida glabrata and Cryptococcus neoformans. Our plan is to initiate a Phase 2 efficacy study to evaluate VL-2397 in the treatment of patients with invasive aspergillosis and we are working with our clinical experts and the FDA towards this objective. Invasive aspergillosis represents a sizeable unmet need given the high mortality rate in immunocompromised patients, despite available antifungal therapies.Vical will conduct a conference call and webcast today, March 9, at noon Eastern Time, to discuss the Company’s financial results and program updates with invited participants. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (913) 312-0639 (preferred), or (888)778-8903 (toll-free), and reference confirmation code 9560352. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 9560352. The call will also be available live and archived through the events page at www.vical.com. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by e-mail at [email protected].About VicalVical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.Forward-Looking StatementsThis press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include net cash use guidance, as well as anticipated developments in independent and collaborative programs, including the plans, timing of initiation, enrollment and announcement of data for clinical trials, plans and timing of regulatory filings and potential markets for Vical’s product candidates. Risks and uncertainties include whether Vical or others will continue development of ASP0113, VCL-HB01 vaccine candidate, VL-2397 or any other independent or collaborative programs; whether Vical will achieve levels of revenues and control expenses to meet its financial projections; whether enrollment in on-going trials will continue at current rates; whether Vical or its collaboration partners will be able to obtain regulatory allowances or guidance necessary to proceed with proposed clinical trials or implement anticipated clinical trial designs; whether on-going or planned clinical trials will be initiated or completed on the timelines Vical currently expects; whether any product candidates will be shown to be safe and efficacious in clinical trials; whether Vical is able to continue its collaborative arrangements or enter into new ones; whether Vical will have access to sufficient capital to fund its planned development activities; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
 VICAL INCORPORATED Selected Condensed Financial Information (Unaudited)               Three Months Ended Twelve Months Ended Statements of OperationsDecember 31, December 31, (in thousands, except per share amounts)2016  2015  2016  2015  Revenues:            Contract revenue $   2,776   $   6,478   $   12,804   $   18,860  License and royalty revenue   387     335     1,727     2,090  Total revenues   3,163     6,813     14,531     20,950  Operating expenses:            Research and development   2,975     2,839     10,355     11,061  Manufacturing and production   1,231     4,301     6,291     10,927  General and administrative   1,732     2,095     7,062     8,366  Total operating expenses   5,938     9,235     23,708     30,354  Loss from operations   (2,775)    (2,422)    (9,177)    (9,404) Net investment and other income   3     67     204     166  Net loss $   (2,772)  $   (2,355)  $   (8,973)  $   (9,238) Basic and diluted net loss per share $   (0.25)  $   (0.26)  $   (0.90)  $   (1.01) Weighted average shares used in computing basic and diluted net loss per share  11,103    9,206    10,019    9,175                                Balance Sheets      December 31, December 31, (in thousands)      2016  2015  Assets:            Cash, cash equivalents, and marketable securities, including restricted       $   38,932   $   39,954  Other current assets         8,935     4,544  Total current assets         47,867     44,498  Long-term investments         2,046     2,052  Property and equipment, net         1,173     1,873  Other assets         1,198     1,491  Total assets       $   52,284   $   49,914               Liabilities and stockholders' equity:            Current liabilities       $   7,145   $   4,162  Long-term liabilities         -     359  Stockholders' equity         45,139     45,393  Total liabilities and stockholders' equity       $   52,284   $   49,914               

Contacts:
Andrew Hopkins
(858) 646-1127
Website: www.vical.com

Anthony Ramos
Vice President and Chief Accounting Officer

Read more...
Vical to Provide Company Update at BIO Asia International Conference

SAN DIEGO, March 09, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (NASDAQ:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook at 10:45 a.m. JST on Tuesday, March 14, at the Biotechnology Innovation Organization (BIO) Asia International Conference (Tokyo – March 14-15). A copy of the presentation will be available through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Tony Ramos
(858) 646-1127
Website: www.vical.com

Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.58
VICL's PB Ratio is ranked higher than
98% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. VICL: 0.58 )
Ranked among companies with meaningful PB Ratio only.
VICL' s PB Ratio Range Over the Past 10 Years
Min: 0.52  Med: 2.06 Max: 7.63
Current: 0.58
0.52
7.63
PS Ratio 1.56
VICL's PS Ratio is ranked higher than
92% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. VICL: 1.56 )
Ranked among companies with meaningful PS Ratio only.
VICL' s PS Ratio Range Over the Past 10 Years
Min: 1.23  Med: 11.72 Max: 48.14
Current: 1.56
1.23
48.14
EV-to-EBIT 1.03
VICL's EV-to-EBIT is ranked higher than
90% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. VICL: 1.03 )
Ranked among companies with meaningful EV-to-EBIT only.
VICL' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.1  Med: -2.8 Max: 266.9
Current: 1.03
-37.1
266.9
EV-to-EBITDA 1.19
VICL's EV-to-EBITDA is ranked higher than
90% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. VICL: 1.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
VICL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -54.6  Med: -3.1 Max: 63.5
Current: 1.19
-54.6
63.5
Current Ratio 6.70
VICL's Current Ratio is ranked higher than
67% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. VICL: 6.70 )
Ranked among companies with meaningful Current Ratio only.
VICL' s Current Ratio Range Over the Past 10 Years
Min: 0.54  Med: 9.87 Max: 35.4
Current: 6.7
0.54
35.4
Quick Ratio 6.70
VICL's Quick Ratio is ranked higher than
68% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. VICL: 6.70 )
Ranked among companies with meaningful Quick Ratio only.
VICL' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 9.87 Max: 35.4
Current: 6.7
0.54
35.4
Days Sales Outstanding 224.44
VICL's Days Sales Outstanding is ranked lower than
92% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. VICL: 224.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
VICL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.06  Med: 81.34 Max: 224.44
Current: 224.44
38.06
224.44
Days Payable 53.50
VICL's Days Payable is ranked lower than
53% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. VICL: 53.50 )
Ranked among companies with meaningful Days Payable only.
VICL' s Days Payable Range Over the Past 10 Years
Min: 7.65  Med: 15.7 Max: 282.72
Current: 53.5
7.65
282.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.40
VICL's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. VICL: -8.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VICL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.8  Med: -8.7 Max: -0.2
Current: -8.4
-24.8
-0.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.92
VICL's Price-to-Net-Cash is ranked higher than
97% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. VICL: 0.92 )
Ranked among companies with meaningful Price-to-Net-Cash only.
VICL' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.72  Med: 2.73 Max: 34.54
Current: 0.92
0.72
34.54
Price-to-Net-Current-Asset-Value 0.64
VICL's Price-to-Net-Current-Asset-Value is ranked higher than
99% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. VICL: 0.64 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VICL' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.61  Med: 2.68 Max: 13.78
Current: 0.64
0.61
13.78
Price-to-Tangible-Book 0.59
VICL's Price-to-Tangible-Book is ranked higher than
98% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. VICL: 0.59 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VICL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.56  Med: 2.34 Max: 13
Current: 0.59
0.56
13
Price-to-Median-PS-Value 0.13
VICL's Price-to-Median-PS-Value is ranked higher than
96% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. VICL: 0.13 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VICL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 1.14 Max: 4.18
Current: 0.13
0.13
4.18
Earnings Yield (Greenblatt) % 96.25
VICL's Earnings Yield (Greenblatt) % is ranked higher than
97% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. VICL: 96.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VICL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 69.9 Max: 117550
Current: 96.25
0.4
117550

More Statistics

Revenue (TTM) (Mil) $14.53
EPS (TTM) $ -0.94
Beta1.14
Short Percentage of Float1.84%
52-Week Range $2.05 - 4.80
Shares Outstanding (Mil)11.10

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 18 29 48
EPS ($) -0.49 -0.09 0.79
EPS without NRI ($) -0.49 -0.09 0.79
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for VICL

Headlines

Articles On GuruFocus.com
Vical to Host Virtual Research & Development Day on May 2, 2017 Apr 24 2017 
Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial Apr 19 2017 
Vical to Provide Company Update at the 29th Annual ROTH Conference Mar 10 2017 
Vical Reports Fourth Quarter 2016 Financial Results Mar 09 2017 
Vical to Provide Company Update at BIO Asia International Conference Mar 09 2017 
CEOs Sell Vical, PhotoMedex, E.W. Scripps, Smart & Final Stores Jan 18 2016 
Red Hat (RHT) and Five Below (FIVE) Strong Performance Metrics; Vical (VICL) Targets Multi-billion S Mar 26 2015 
John Rogers Comments on Vical Feb 26 2014 
Kids Decide on Dolls or Devices - JAKK, Others 70% Off Sep 17 2013 
Weekly CFO Buys Highlight: VICL, EXA, UCBA, YORW, MGI Jan 21 2013 

More From Other Websites
Vical to Host Virtual Research & Development Day on May 2, 2017 Apr 24 2017
Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial Apr 19 2017
ETFs with exposure to Vical, Inc. : April 5, 2017 Apr 05 2017
Vical, Inc. :VICL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017 Mar 15 2017
Vical to Provide Company Update at the 29th Annual ROTH Conference Mar 10 2017
Vical to Provide Company Update at BIO Asia International Conference Mar 09 2017
Vical reports 4Q loss Mar 09 2017
Vical Reports Fourth Quarter 2016 Financial Results Mar 09 2017
Investor Network Invites You to the Vical Fourth Quarter 2016 Earnings Webcast Live on Thursday,... Mar 08 2017
Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2016 Financial Results Mar 02 2017
Vical Provides Company Update at Biocom's Global Life Science Partnering Conference Feb 24 2017
Vical Provides Company Update at BIO CEO and Investor Conference Feb 07 2017
ETFs with exposure to Vical, Inc. : January 6, 2017 Jan 06 2017
ETFs with exposure to Vical, Inc. : December 13, 2016 Dec 13 2016
ETF’s with exposure to Vical, Inc. : November 7, 2016 Nov 07 2016
Investor Calendar Invites You to the Vical Third Quarter 2016 Earnings Webcast Live on Thursday,... Nov 02 2016
ETF’s with exposure to Vical, Inc. : October 25, 2016 Oct 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)